Aarti Industries Q3 FY26 Earnings Transcript Released, Discusses Global Trade Shifts
Aarti Industries released its Q3 FY26 earnings call transcript. Revenue rose 11% Q-o-Q to ₹2,492 crore, with PAT up 25% to ₹133 crore. The company highlighted positive impacts from India-EU FTA, China's 'anti-involution' strategy, and US-India trade deal. MMA capacity is being scaled up, and Zone 4 CAPEX is projected at ₹1,100 crore for the year.
The transcript provides detailed insights into financial performance and strategic direction, including capacity expansions and global trade impacts, which are material for investors.
The announcement details positive financial performance, strategic initiatives, and favorable global trade developments, indicating a positive outlook for the company.
Aarti Industries Limited has released the transcript of its Q3 FY26 earnings conference call, held on February 3, 2026. The call featured insights from Executive Director and CEO, Mr. Suyog Kotecha, and CFO, Mr. Chetan Gandhi.
During the call, management discussed the challenging global operating environment characterized by geopolitical tensions and trade realignments. They highlighted three major events expected to positively impact the chemical sector: the India-EU Free Trade Agreement (FTA), China's 'anti-involution' strategy aimed at curbing hyper-competition and excess capacity, and the US-India Trade deal providing relief from tariff disruptions.
Financially, Q3 FY26 revenue stood at ₹2,492 crore, an 11% increase quarter-on-quarter, driven by volume growth in products like MMA, NT, and DCB. EBITDA surged by 11% Q-o-Q to ₹323 crore. Profit After Tax (PAT) increased by 25% Q-o-Q to ₹133 crore, despite a one-time exceptional expense of ₹15 crore for the implementation of the new labor code.
Exports constituted 65% of total revenues. The company is scaling up MMA capacity to 360 KT by Q4FY26 and debottlenecking DCB capacity from 120 to 140 KTPA. The total CAPEX for the year is estimated at ₹1,100 crore, with Zone 4 CAPEX expected to be between ₹1,600 crore and ₹1,800 crore, with the majority deployed by the end of the current fiscal year. Future CAPEX for FY27 is anticipated to be significantly lower.
Joint ventures with Superform and RESL are progressing well, with commissioning expected in Q1FY27 and H1FY27, respectively. Management expressed confidence in the company's trajectory as an innovation-led global chemicals leader, supported by structural tailwinds and internal digital and AI-driven productivity gains.
What to do with a filing like this
Aarti Industries Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarti Industries Limited. Read the original for the full detail.